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The thrombopoietin/MPL axis is activated in the Gata1low
mouse model of myelofibrosis and is associated with a
defective RPS14 signature
M Zingariello1, L Sancillo2, F Martelli3, F Ciaffoni3, M Marra3, L Varricchio4, RA Rana2, C Zhao5, JD Crispino5 and AR Migliaccio4,6
Myelofibrosis (MF) is characterized by hyperactivation of thrombopoietin (TPO) signaling, which induces a RPS14 deficiency that
de-regulates GATA1 in megakaryocytes by hampering its mRNA translation. As mice carrying the hypomorphic Gata1low mutation,
which reduces the levels of Gata1 mRNA in megakaryocytes, develop MF, we investigated whether the TPO axis is hyperactive in
this model. Gata1low mice contained two times more Tpo mRNA in liver and TPO in plasma than wild-type littermates. Furthermore,
Gata1low LSKs expressed levels of Mpl mRNA (five times greater than normal) and protein (two times lower than normal) similar to
those expressed by LSKs from TPO-treated wild-type mice. Gata1low marrow and spleen contained more JAK2/STAT5 than wild-type
tissues, an indication that these organs were reach of TPO-responsive cells. Moreover, treatment of Gata1low mice with the JAK
inhibitor ruxolitinib reduced their splenomegaly. Also in Gata1low mice activation of the TPO/MPL axis was associated with a RSP14
deficiency and a discordant microarray ribosome signature (reduced RPS24, RPS26 and SBDS expression). Finally, electron
microscopy revealed that Gata1low megakaryocytes contained poorly developed endoplasmic reticulum with rare polysomes. In
summary, Gata1low mice are a bona fide model of MF, which recapitulates the hyperactivation of the TPO/MPL/JAK2 axis observed
in megakaryocytes from myelofibrotic patients.
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INTRODUCTION
A number of studies have shown that the myeloproliferative
neoplasm myelofibrosis (MF) is caused by genetic abnormalities
involving the thrombopoietin (TPO) axis, including mutations in
JAK2, the TPO receptor MPL or in calreticulin (CALR).1 All three
classes of mutations lead to hyperactive JAK/STAT signaling.
Furthermore, patients with MF also have elevated serum TPO
levels.2 These mutations, however, are also found in the related
myeloproliferative neoplasm diseases polycythemia vera and
essential thrombocythemia, prompting the hypothesis that the
disease phenotype is determined by a genetic modifier yet to be
identified. The observation that MF is specifically associated with
reduced GATA1 content in megakaryocytes3 has suggested that
this abnormality may be a phenotypic modifier in MF. The
‘element’ that specifically links TPO signaling with de-regulated
GATA1 expression in megakaryocytes is, therefore, subject of
investigation. We have recently presented data suggesting that
this ‘element’ is represented by enrichment of ribosomal path-
ways gene signatures, which was associated with impaired GATA1
translation in megakaryocytes4,5
Support for the role of GATA1 deficiency in megakaryocytes as
the ‘phenotype modifier’ in MF was provided by the observation
that mice carrying a hypomorphic mutation (Gata1low) that deletes
the hypersensitive site (HS1), which drives transcription of Gata1
in megakaryocytes,6 develop MF.7 Although Gata1low mice are not
anemic,7 they are subjected to continuous erythroid stress due to
the reduced half-life of their erythrocytes.8 The animals recover
from this stress by activating an alternative erythroid differentia-
tion pathway in the spleen, which involves the production of
specific bipotent erythroid/megakaryocyte precursors.8,9 The
phenotype of the stress precursors identified in Gata1low mice is
different from that identified by Paulson et al.,10 which is induced
by acute stress, and is similar to that of the bipotent erythroid/
megakaryocyte precursors generated in vitro by human CD34+
cells in response to a chemical MPL hyperstimulator,11 leading us




Male wild-type and Gata1low mice were originally obtained from Dr
S Orkin12 and outbread in the animal facility of Istituto Superiore di Sanità
as described.7,13 Littermates were genotyped at birth by PCR,13 and those
found not to carry the mutation were used as wild-type controls. Mplnull
mice were provided by Dr W Alexander.14 All the experiments were
performed according to the protocols approved by the institutional animal
care committee according to the European Directive 86/609/EEC.
Treatments
Bleeding. A volume of 200 μl of blood was collected from wild-type mice
through the retro-orbital plexus. Mice were killed by cervical dislocation
24 h later and their tissues removed for further analyses.
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TPO treatment. Wild-type mice (9–10 months old) were treated
intraperitoneally with of TPO (100 μg/kg/day for 5 days in saline).
Ruxolitinib. Nine- to ten-month-old Gata1low mice (four males and four
females per experimental group) were treated with Ruxolitinib (Rux;
#S1378 INCB 018424; Selleckchem, Houston, TX, USA; 45 mg/kg twice
per day by gavage in 2% v/v dimethylsulfoxide in H2O) and vehicle (2% v/v
dimethylsulfoxide in H2O) for 5 consecutive days, rested for 2 days and
then treated for 5 additional days.15 On day 17, mice were weighed, bled
for blood parameters determinations and killed for organ histopathology
observations. Results are compared with those observed in historic wild-
type controls.16,17 Hematocrit and platelet counts were determined
manually.
Flow cytometry and cell sorting
Lineage negative cells were labeled with fluorescein isothiocyanate-
conjugated Scal, phycoerythrin-conjugated anti-CD117 (cKit) (LSK cells)
and anti-MPL antibody (AMM2, Kirin Pharmaceuticals, Tokyo, Japan)18,19 or
irrelevant isotype-matched antibodies. Cell fluorescence was analyzed with
a FACS ARIA cell sorter (Becton Dickinson, Franklin Lakes, NJ, USA) and
expressed as mean fluorescent intensity. LSK were isolated as described.20
Enzyme-linked immunosorbent assay for TPO
The levels of TPO present in platelet-poor plasma and organ washes were
measured by enzyme-linked immunosorbent assay (Quantikine Immu-
noassay mouse TPO; R&D Systems, Inc., Minneapolis, MN, USA), according
to the manufacturer’s instructions. Platelet-poor plasma was prepared by
centrifugation at 5000 r.p.m.; blood collected with ethylenediaminetetraa-
cetic acid-coated microcapillary tubes (20–40 μl/sampling). Organ washes
were prepared as described.21
RNA isolation, quantitative reverse transcription-PCR and
microarray analyses
Total RNA was prepared with Trizol (Gibco-BRL, Grand Island, NY, USA) and
reverse transcribed with random primers using the superscript III kit
(Invitrogen Life Technologies, Bethesda, MD, USA). Gene expression levels
were quantified by quantitative reverse transcription-PCR using TaqMan
Universal PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) and
commercial primers (inventoried TaqMan Gene Expression Assays (Applied
Biosystems). GAPDH or β-actin were used as control as described by the
manufacturer. Reactions were performed in an ABI 7300 Real Time PCR
System (Applied Biosystems). Cycle threshold (Ct) was calculated with the
SDS software Version 1.3.1 (Applied Biosystems), and mRNA levels were
expressed as 2−ΔCt (ΔCt = target gene Ct−GAPDH Ct). For microarray
analyses, total RNA was extracted from the bone marrow and spleen of 8-
to 10-month-old Gata1low and wild-type littermates and purified with
Rneasy Mini Kit (Qiagen, Germantown, MD, USA). Hybridization to Illumina
Mouse WG-6V2 Bead Chip gene expression array was performed by the
Microarray Resource Facility, Icahn School of Medicine at Mount Sinai.
Functional Annotation Clustering was performed with the David
Bioinformatic Database (David Bioinformatics Resources 6.7 NIAID/NIH).




Protein extracts separated on SDS-polyacrylamide gel electrophoresis,
were blotted on nitrocellulose membranes and probed with antibodies
against JAK2 (D2E12 #3230), pSTAT5 (#9351), Ezh2 (Ac22 #3147), SMAD2/3
(#5339), p38 (#9213) and p-p38 (T180/Y182 #4511) (all from Cell Signaling,
Boston, MA, USA), STAT5 (#sc-835, Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and GAPDH (#CB1001, Calbiochem, San Diego, CA, USA).
Histology
Tissues were fixed in 10% (v/v) phosphate-buffered formalin according to
standard procedures,16 paraffin-embedded and cut into consecutive 2.5–
3 μm sections that were then stained either with either hematoxylin–eosin
and Gomori silver (MicroStain MicroKit, Bologna, Italy), or immunostained
with anti-transforming growth factor (TGF)-β1 (sc-146, Santa Cruz
Biotechnology) antibodies. Immunoreactions were detected with STAT-Q
Peroxidase–AEC Staining System Kit (Innovex Biosciences, Richmond, CA,
USA). Images acquired with the Light microscope (ZEISS, Axioskop,
Germany) equipped with a Coolsnap Videocamera were quantified with
the MetaMorph 6.1 Software (Universal Imaging Corp., Downingtown, PA,
USA). Electron microscopyand immuno-electron microscopy observations
were performed as described previously.16,17
Statistical analyses
Results were analyzed by analysis of variance (Windows Origin 6.0,
Microcal Software Inc., North Hampton, MA, USA), Wilcoxon–Mann–
Whitney test (two-sided) or multi-regression modeling (SAS software
v9.2, SAS Institute, Cary, NC, USA). For microarray, Bonferroni-corrected
P-values o0.05 were regarded as a statistically significant association.
Gene set enrichment analysis was used to identify pathways that were
altered in Gata1low mice as described.22
RESULTS
Gata1low mice express high levels of TPO
TPO mRNA was expressed not only, as expected,23 by the liver and
kidney but also by all hematopoietic tissues (spleen, bone marrow
and bone) and tissues containing TPO-responsive mast cells (ear,
stomach and intestine)24,25 both Gata1low mice and wild-type
littermates (Table 1). In wild-type mice, the greatest levels of TPO
mRNA were detected in the liver (430-fold than any other tissue),
followed by kidney and intestine. The liver and stomach from
Gata1low mice expressed levels of TPO mRNA 2- to 3-fold greater
than normal while TPO mRNA levels were 10-fold lower than
normal in their bone, bone marrow and spleen. This altered
pattern of TPO mRNA tissue distribution appears to be unique to
Gata1low mice as bleeding or genetic Mpl ablation had modest
effects on the levels of TPO mRNA expressed by tissues from mice
wild type at the Gata1 locus. The great levels of TPO mRNA
expressed by the liver from Gata1low mice are consistent with the
great levels of interleukin-6, the major regulator of TPO
production by the liver,26 expressed by these mutants.16
By enzyme-linked immunosorbent assay, TPO protein was
detected in the plasma and in washes from all the tissues
investigated (bone marrow, spleen, liver and peritoneum; Table 1).
As expected27,28 the greatest levels of TPO protein were detected
in the plasma, and these levels were increased by bleeding (by
30%) and Mpl (by threefold) ablation.29 Also the plasma from
Gata1low mice contained levels of TPO threefold higher than
normal (778 ± 101 vs 351 ± 31 pg/ml) and only two times lower
than those of the plasma from mice carrying the Mplnull mutation
(1287± 205 pg/ml; Table 1).
The plasma concentration of TPO is mainly regulated by
intracellular degradation following binding to its receptor Mpl by
megakaryocytes30 and platelets.31 The increased production of
TPO mRNA by the liver and the greater than normal TPO
concentration in the plasma of Gata1low mice in spite of the
numerous megakaryocytes expressing surface levels of MPL two
times greater than normal (MPL mean fluorescence intensity ~ 200
vs 600 per wild-type and Gata1low CD61+CD41+ cells, respectively)
present in their bone marrow and spleen indicate that Gata1low
mice contain levels of TPO greatly higher than normal and
possibly similar to those reported to induce fatal MF in mice
(range 800–8000 pg/ml).32
In conclusion, Gata1low mice express high levels of TPO mRNA in
the liver and levels of TPO protein in plasma similar to those which
induce MF in mice.
LSK from Gata1low mice express a MPL pattern suggestive of
receptor activation
We next compared the levels of MPL (mRNA and protein)
expressed by LSK from Gata1low and wild-type littermates
(Figures 1a–c). Although Gata1low LSK contained levels of Mpl
mRNA three times greater than that expressed by wild-type cells,
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Figure 1. The TPO/MPL axis is activated in LSK from Gata1low mice. (a) Representative flow cytometry determinations of cell-surface expression
of Mpl in LinnegSca1+Kit+ (LSK) cells from wild-type mice, either untreated or treated with TPO, and untreated Gata1low mice. (b) Quantitative
reverse transcription-PCR determinations of the levels of Mpl mRNA expressed by LSK cells from wild-type mice, either untreated or treated
with TPO, and from untreated Gata1low mice (six mice per experimental group). Results are expressed as mean (± s.d.) of relative values when
compared to those from untreated wild-type mice. (c) Mean fluorescence intensity (MFI) determinations of the cell-surface expression of MPL
by LSK cells in the same groups analyzed in a. Results are expressed as mean (± s.d.) with six mice per experimental point. *Po0.05 with
respect to wild-type mice by analysis of variance.
Table 1. The liver and the plasma from Gata1low mice express greater levels of TPO mRNA and protein than that of piastrinopenic mouse models
(bled wild-type mice and Mplnull mice)
Wild type Wild type, bleeding Gata1low Mplnull
Blood values
Hct (%) 47.8 (±0.3) 43.1 (±1.1)a 45.0 (±3.3) 42.3 (±1.3)a
Plt/μl (×106) 0.9 (±0.03) 0.7 (±0.03)a 0.3 (±0.01)† 0.03 (±0.004)a
TPO mRNA (2−ΔCt)(× 10−3)
Liver 39.3± 7 41.3± 4.3 94.2± 9.5a 35.5± 10.5
Spleen 1.3± 0.1 0.5± 0.2 0.02± 0.002a ND
Bone marrow 0.1± 0.006 3± 1a 0.007± 0.001a 0.01± 0.002a
Bone 1.9± 0.5 0.5 0.3± 0.1a BD
Ear BD 1.2 0.06± 0.005 BD
Kidney 6.2± 0.001 7.6± 0.9 10.6± 1.3 8.9± 2.1
Stomach 0.7± 0.1 0.3± 0.03a 4.6± 0.9a 1.0± 0.1
Intestine 4.0± 0.2 8.2± 2.0 2.9± 0.7 2.2± 0.1a
TPO protein (pg/ml)
Plasma 351± 31a 451± 11a 778± 101a 1287± 205
Bone marrow 98± 13 96± 14a 25± 1a 47± 13
Spleen 99± 15 140± 4 66± 3 119± 7
Liver 289± 28 179± 6a 166± 10a 271± 74
Peritoneum 93± 2 88± 3 45± 5a 97± 15
Abbreviations: BD, below detection; Hct, hematocrit; ND, not done; Ptl, platelet counts; TPO, thrombopoietin. Blood values and TPO mRNA and protein levels
in tissues from wild-type and Gata1low and Mplnull piastrinopenic mice. Results are presented as mean (± s.d.) of those obtained with three mice per
experimental group. aValue statistically different (Po0.01 by analysis of variance) from those observed in wild-type mice.
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their MPL surface expression was two times lower than that of LSK
cells from untreated wild-type mice. Similar increments in levels of
MplmRNA and decrements in levels of MPL cell-surface expression
were observed with LSK from wild-type mice subjected to TPO
treatment. As with other hematopoietic growth factors, TPO
engaging to MPL results in receptor downmodulation followed by
activation of de novo gene translation.33 Therefore, the similarity in
the levels of MplmRNA and cell-surface protein observed between
TPO-treated and Gata1low LSK indicates that the MPL signaling in
LSK from Gata1low mice is hyperactive. Of note, also CD34+ cells
from MF patients express cell-surface MPL levels lower than
normal34 possibly resulting from exposure to TPO levels greater
than normal3 and may indicate pathway hyperactivation as
well.35,36
Bone marrow and spleen from Gata1low mice contain levels
greater than normal of signaling elements downstream to the TPO
and TGF-β signaling
To assess the cellular consequences of TPO/MPL activation in
Gata1low mice, the content of its downstream partners JAK2 and
STAT5 of bone marrow and spleen from Gata1low and wild-type
littermates was compared by western blot analyses (Figures 2a
and b). JAK2, STAT5 and pSTAT5 were barely detectable in the
bone marrow from wild-type mice but were strikingly elevated in
that from the mutant animals. JAK2, and to a lesser extent pSTAT5
staining was also elevated in the spleen from Gata1low mice. These
results suggest that the cellular compartments that respond to
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Figure 2. Bone marrow and spleen from Gata1low mice contain levels greater than normal both of signaling elements downstream to TPO and
of those downstream to TGF-β. (a, b) Western blot determinations of the JAK2, STAT5 and pSTAT5 content of bone marrow and spleen from
wild-type and Gata1low mice (each lane). GAPDH was used as loading control. Quantification was obtained by normalizing each band to the
corresponding GAPDH level and is presented as mean (± s.d.) with three mice per experimental group. P-values were determined by analysis
of variance (ANOVA). (c, d) Western blot determinations of the SMAD2/3, phosphorylated p38 (p-p38), p38 and EZH2 content in the bone
marrow and spleen from wild-type and Gata1low mice (each line a different mouse). GAPDH was used as a loading control. Quantification was
obtained by normalizing p-p38 toward the corresponding p38 band, and SMAD2/3, p38 and EZH2 signals against GAPDH. P-values were
calculated by ANOVA. EZH2, enhancer of zeste homolog 2.
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We have previously shown that Gata1low mice, as MF patients,
express levels of TGF-β greater than normal and an activated TGF-
β signaling profile.37,38 To compare the cellular alterations induced
by TPO and TGF-β activation, the content of elements of the
canonical (SMA2/3) and non-canonical (p38) TGF-β signaling, in
the bone marrow and spleen from wild-type and Gata1low
littermates was also evaluated (Figures 2c and d). Gata1low mice
express levels of p38 phosphorylation two times greater than
normal in the bone marrow and of SMAD2/3 two times greater
than normal in the spleen. Interestingly, the histone-lysine N-
methyltransferase enzyme enhancer of zeste homolog 2, which is
part of the polycomb repressive complex 2 subunit activated by
nuclear factor-kB downstream to the p38 pathway,39 was also
expressed at levels 410 times greater than normal in the spleen
suggesting that although undetected by our analyses, the p38
pathway is also activated in the spleen from Gata1low mice.
Together these results show that the cellular compartments that
respond to TPO are mostly expanded in the bone marrow while
those that respond to TGF-β are mostly expanded in the spleen
from Gata1low mice.
Rux reduces extramedullary hematopoiesis but does not halt
disease progression in Gata1low mice
The role exerted by JAK2 on the myelofibrotic phenotype
expressed by Gata1low mice was assessed by treating three
females and three males with the Food and Drug Administration-
approved JAK inhibitor Rux. Rux also had little effect on the body
weight but gave rise to reduced hematocrit and modestly
increased platelet counts in the female group (Figures 3a and b).
The treatment had little effect on the JAK2/STAT5 protein
content within the bone marrow (data not shown) and on the
STAT5 content of the spleen, but led to a twofold reduction in
JAK2 within the spleen (Figure 3c), suggesting that the treatment
had little effects of the cellular composition of the bone marrow
but reduced the cells in the spleen, which express JAK2. In
agreement with this interpretation, Rux led to a remarkable
reduction in spleen size (with respect to both weight and cell
number) and restored the splenic architecture both in females and
males (Table 2 and Figure 3d). However, it had no effect on bone
marrow cellularity, which remained lower than normal (Table 2).
Rux also had no effect on the frequency of megakaryocytes in the
bone marrow, which remained greater than normal, but
decreased the frequency of these cells in the spleen (Figures 3d
and e). Finally, Rux modestly reduced fibrosis in the bone marrow
but not in the spleen (Figures 3d and e). The modest effects
exerted by Rux on fibrosis were confirmed by the presence of
similar great number of tear drop poikilocytes, that is, reticulocytes
with the typical morphological deformation acquired when they
pass through fibrotic meshes, observed in blood from vehicle- and
Rux-treated mice (data not shown).
We had previously confirmed that in Gata1low mice altered
levels of TGF-β are causative for MF by demonstrating that
treatment with an inhibitor of the TGF-β receptor 1 kinase AKL5
Figure 3. See next page for caption.
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for a duration similar to that investigated here for Rux rescued
both their abnormal TGF-β signaling and their myelofibrotic
phenotype.15,16 To gain insights on the mechanism of action of
Rux in this animal model, we investigated the levels of TGF-β in
the bone marrow and the spleen of Gata1low mice treated either
with Rux or with vehicle (Figure 4). As expected,16 by immuno-
histochemistry both bone marrow and spleen from vehicle-
treated Gata1low mice expressed great levels of TGF-β, and the
Figure 3. Treatment with Rux reduces JAK2 and restores the architecture of the spleen of Gata1low mice. (a, b) Determination of body weight,
hematocrit (Htc) and platelet counts (Ptl) in female (a) and male (b) Gata1low mice treated for 2 weeks with either vehicle (V) or Rux, as
indicated. For the group of males, determinations observed before treatment (pre) are also depicted. Results are presented as mean (± s.d.)
with three mice per group and are compared with mean (± s.d.) observed in historic wild-type littermates, indicated by the horizontal boxes.
*Po0.05 (by analysis of variance (ANOVA)) with respect to V. (c) Western blot analyses of JAK2 and STAT5 in spleen from Gata1low mice treated
either with vehicle (V) or Rux (T) (each lane a separate animal). Quantification of results obtained with three to four mice per group is
presented on the right. P-values were calculated by ANOVA. (d) Representative hematoxylin–eosin (top and middle panels on the left) and
Gomori silver (bottom panels on the left) stains of bone marrow and spleen sections from Gata1low mice treated with either vehicle or Rux, as
indicated. Note that the spleen of the Rux-treated mouse presents the typical dark red color of this organ with areas of white pulp (blue
circles) appropriately located in germinal centers in the subcapsular area. By contrast, the spleen from vehicle-treated mouse has a
disorganized morphology with excessive red pulp areas and paucity of white pulp areas localized mostly in the middle of the parenchyma.
Original magnification ×4, × 10 and × 40, as indicated. Representative megakaryocytes are indicated by arrow. (e) Computer-assisted
quantification of the frequency of megakaryocytes (MK) and of the intensity of Gomori silver staining of bone marrow (BM) and spleen from
Gata1low mice treated with either vehicle or Rux (three mice per experimental group). *Po0.05 by ANOVA.
Table 2. Treatment of Gata1low mice with ruxolitinib decreases splenomegaly but has modest effects on blood values and bone marrow cellularity
Mouse Spleen Cells/femur ( ×106)
Weight (mg) Length (cm) Cells (×106)
V (n= 6) 343.3± 86.9 2.6± 0.2 237.9± 79.7 8.6± 1.9
T (n= 6) 231.7± 43.1a 2.5± 0.3 145.7± 66.8a 11.5± 9.4
WT (n= 12) 100.0± 10.0 NA 159.0± 22 16.2± 1.8
Gata1low(n= 12) 430.0± 45.0 3.1 393.0± 38.0 9.7± 0.7
Abbreviations: NA, not available; T, treatment; V, vehicle; WT, wild type. aValue statistically different (Po0.05) from those observed in wild-type mice.
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staining was mainly localized with the megakaryocytes (Figures 4a
and b). Treatment with Rux decreased by threefold the levels of
TGF-β detected in the bone marrow and down to barely
detectable in the spleen. The greater effects exerted by Rux on
the levels of TGF-β present in the spleen than in the bone marrow
are consistent with the fact that this treatment significantly
reduced the frequency of megakaryocytes only in the spleen.
In conclusion, these results indicate that Rux rescues the
myelofibrotic traits, normalizing the TGF-β of the spleen but is
only partially effective in rescuing the defective hematopoiesis of
the bone marrow from Gata1low mice.
Gata1low mice express a ribosomal signature predictive of
ribosomal deficiency
We have previously demonstrated that although megakaryocytes
from Gata1low mice contain levels of Gata1 mRNA only twofold
lower than normal, the GATA1 protein in these cells is barely
detectable.7,9 We had attributes this discrepancy to a predicted
low sensitivity of immunohistochemistry. However, the demon-
stration that activation of TPO/MPL/JAK2 signaling induces a
ribosomal deficiency within megakaryocytes derived from MF
patient stem cells, which hampers GATA1 mRNA translation in
ex vivo-expanded megakaryocytes,5 and the realization that
Gata1low mice express an activated TPO pathway (this manuscript)
made us question the original hypothesis that reduced content of
GATA1 in Gata1low megakaryocytes is solely the consequence of
deletion of the lineage-specific enhancer. To clarify this point we
performed microarray analyses of the bone marrow and the
spleen from Gata1low and wild-type littermates of comparable age
(all 10- to 13-month-old males). This analysis identified differential
expression of numerous genes between Gata1low and wild-type
littermates. The majority of these genes were in pathways related
to inflammation/autoimmunity, including the TGF-β pathway (see
GSE89630). Among the differentially expressed genes in the bone
marrow, there was a strong discordant ribosome signature, which
reached statistical significance for two genes of the large subunit
(RLP36AL and RPL27A, both activated in Gata1low bone marrow)
and four genes (RSP6KA1 and RSP9 activated; RSP24 and RSP26
repressed) of the small subunit (Figure 5a). In addition, there was a
significant decline in the mRNA levels for the ribosome maturation
protein SBDS, which has been implicated in the joining of the 40S
and 60S subunits during the ribosome biogenesis.40 Of interest,
hypomorphic mutations of RSP24 and RSP26 are observed in a
subset of patients with Diamond Blackfan anemia, a disease due
to inefficient translation of GATA1 mRNA,41 and loss-of-function
mutation of SBDS are associated with the Shwachman–Diamond
syndrome,42 one of the inherited bone marrow failure syndromes
with a disease manifestation predictive of ribosomopathy.
A limitation of these results is that they were obtained on mRNA
prepared from the entire tissue and therefore were not selective
to megakaryocytes. This caveat was addressed by performing a
careful electron microscopy study, which confirmed that the
cytoplasm of megakaryocytes from Gata1low mice contain a poorly
developed endoplasmic reticulum with rare isolated polysomes, a
clear indication of reduced ribosome biogenesis (Figure 5c).
Next, we used gene set enrichment analysis22 to identify
pathways that are dysregulated in bone marrow and spleen cells
of Gata1low mice. As expected, we observed significant enrich-
ment of a gene set derived from a set of known GATA1 erythroid
cell target genes in cells from the bone marrow (Figures 6a and c).
Among other gene sets (Supplementary Table S1), we also
observed enrichment of the RPS14 gene signature, which was
derived from the changes seen upon knockdown of RPS14 in
erythroid cells43 (Figures 6b and d). In contrast, we did not detect
significant changes in ribosome gene mRNA levels (Figure 5b) or
downregulation of the RPS14 pathway in the spleen of Gata1low
mice (data not shown). Gene set enrichment analysis further
revealed that additional enriched pathways include the cell cycle
(including E2F and RB) and transcription, such as GLI1 and HOXA9,
the nuclear translocation of which is regulated by TPO44
(Supplementary Table S1).
Together, these results suggest that as observed in the
patients,5 activation of the TPO/MPL pathway, through mechan-
ism(s) still unclear, induces in Gata1low mice a RSP14 deficiency,
which contributes to reduce the GATA1 content in the mega-
karyocytes of these mice. Reduction of GATA1 content then likely
contributes to exacerbate the ribosomal gene defect, perhaps by
directly regulating expression of a subset of ribosome genes.
Indeed, a recent report showed that GATA1 binds to a subset of
ribosome genes, including RPS19 and RPS26.45
DISCUSSION
In this manuscript, by showing that Gata1low mice express a
hyperactive TPO/MPL axis, we provide new insights on the
mechanism(s) that leads to recovery from chronic anemia, on the
differences between regulation of Gata1 in erythroid cells and
Figure 4. Rux decreases the TGF-β content of the bone marrow and the spleen from Gata1low mice. (a) Representative immunostaining with
TGF-β antibodies of bone marrow (BM) and spleen sections from Gata1low mice treated with either vehicle or Rux, as indicated. Magnification
× 40. (b) Computer-assisted quantification of the intensity of TGF-β immunostaining of bone marrow and spleen sections of the groups
presented in a. Results are presented as mean (± s.d.) of those obtained by evaluating three to four sections per mouse, three mice per group.
P-values were calculated by analysis of variance.
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Figure 5. Bone marrow from Gata1low mice express a discordant ribosomal signature and contain megakaryocytes with poorly developed
endoplasmic reticulum and reduced numbers of polysomes. Summary of the fold-change with respect to wild type in the expression of genes
for the large (top) and small (bottom) subunit of the ribosomes in bone marrow (a) and spleen (b) from Gata1low mice. Results are expressed as
log fold increase. Value statistically different (Po0.05) from those observed in wild-type mice are indicated by *. (c) Transmission electron
microscopy of representative megakaryocytes from wild-type (WT) and Gata1low littermates. Megakaryocytes were recognized by their
distinctive morphology shown in the low magnification presented in the top panels. Details of the perinuclear area of the cells (indicated by
the red square) showing the poorly developed rough endoplasmic reticulum with reduced numbers of polysomes (indicated by the yellow
circles) are shown in the photographs obtained at greater magnification in the bottom panels. To be noted that the Gata1low megakaryocyte is
smaller and less mature than the wild-type one. Similar results were obtained by analyzing at least five separate megakaryocytes from three
mice per group.
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megakaryocytes, and on our understanding on how to ameliorate
therapies for MF.
Seminal work by Dr Paulson has clarified how the combination
of BMP4, soluble stem cell factor and glucocorticoid receptor
signaling activates microenvironmental cues in the spleen, which
allows recovering from acute stress.10 By contrast, the mechan-
isms that lead to recovery from chronic stress, such as those that
mediates the expansion of the erythroid compartments in
congenic hemoglobinopathies, or during chronic inflammation,
are still poorly understood. Studies from the Rivella laboratory had
indicated that to recover from chronic anemia, mice, and possibly
humans, activate a pathological interaction between erythroblasts
and their macrophage niches, which leads to ineffective
erythropoiesis.46 This interaction is restricted by treatment with
Rux, indicating that is sustained by JAK signaling activated by
unknown cytokines. Also Gata1low mice suffer from chronic
anemia, which is compensated by extramedullary hematopoiesis
in the spleen. The data presented in this manuscript suggest that
the chronic stress pathway in the spleen is activated by TPO and
its downstream JAK-dependent signaling.
The regulatory regions of the Gata1 gene include three
hypersensitive sites (HSs).47 The hypomorphic Gata1low mutation
deletes the distal HS1 sites12 and reduces by two- to threefold the
levels of Gata1 mRNA in the bipotential megakaryocytic/erythroid
progenitor cells, in erythroid cells, megakaryocytes and dendritic
cells.20 The mice are born anemic but those that may activate
efficiently extramedullary hematopoiesis in the spleen remain
thrombocytopenic, recover from anemia soon after birth and have
a normal lifespan.7 As GATA1 is indispensable for erythroid
maturation, the question is raised on the mechanisms that rescue
erythropoiesis in the spleen of these animals. In addition to HS1,
the Gata1 gene contains an additional enhancer HS2. By using a
reporter gene driven by HS2, we demonstrated that HS2 is active
in erythroid and megakaryocytes from the spleen, but not in those
from the bone marrow indicating that activation of mRNA
translation from this alternative site may rescue Gata1 deficiency
in the spleen.48 However, although HS2 is active both in erythroid
cells and megakaryocytes, erythroid cells from the spleen contain
normal levels of GATA1 protein while the levels of GATA1 protein
detectable by immunohistochemistry in megakaryocytes remain
low.7,9 This observation raises the question on the mechanism that
reduces the GATA1 protein in the megakaryocytes from the
spleen in this mouse model. The microarray analyses described in
this paper indicate that the bone marrow, which contains mainly
megakaryocytes, express a ribosomal deficiency while the spleen,
which contain mainly erythroblasts, does not. In addition, electron
microscopy observation indicated that megakaryocytes from both
bone marrow and spleen have a poorly developed rough
endoplasmic reticulum and contain few ribosomes. These
observations suggest that as in myelofibrotic patients, in Gata1low
mice an activated TPO/MPL axis induces a ribosomal deficiency in
the megakaryocytes, but not in the erythroid cells, which results in
thrombocytopenia due to reduced Gata1 mRNA translation.
MF is the most severe of the Philadelphia chromosome-
negative myeloproliferative neoplasms and is characterized by a
wide range of constitutional symptoms and short survival.49
Although a large European study found that the median survival
of patients with MF has improved from 4.6 years in 1980–1995 to
6.5 years in 1996–2007, long-term survival of these patients
remains low.50 In 2005, the discovery of the activating JAK2V617F
mutation in ~ 50–60% of the patients with MF51–54 led to the
development of a number of pharmacological inhibitors of Janus
Kinases for the treatment of this disease. However, despite the
large numbers of JAK inhibitors that were developed and tested
for the treatment of MF, only one, Rux, was demonstrated by the
large COMFORT clinical trial to markedly improve splenomegaly
and MF-associated symptoms over placebo or best available
therapy55,56, and has been approved by the Food and Drug
Administration for clinical use in this disease.57 Many other JAK
inhibitors have been discontinued or are under consideration for
other indications related to chronic inflammation, such as
rheumatoid arthritis.58 However, even Rux has modest effects on
bone marrow fibrosis and does not decrease the mutant JAK2
allele burden,57 leading to questions whether this agent is a truly
modifying agent in MF. Although multiple analyses of the Rux
trials have shown a survival advantage for Rux -treated
patients,55,56 it has been argued that the drug may improve
survival by improving appetite, weight and correcting cachexia as
a result of a robust suppression on inflammatory cytokines some
of which have been shown as independent predictors of poor
survival in MF.59 It is currently debated whether Rux may exert
some of its functions indirectly, by inhibiting JAK signaling
mediated by the pro-inflammatory milieu of the
microenvironment.
Although Rux does not affect ALK5 (IC60 = 6907 nM),60 the TGF-β
receptor 1 kinase whose inhibition rescued MF in Gata1low mice,
Figure 6. The GATA1 and RPS14 gene signatures are enriched in
Gata1low bone marrow. Gene set enrichment analysis (GSEA)
revealed that the GATA1 and RPS14 gene signatures are enriched
in Gata1low mice. (a, b) GSEA plots for GATA1 (a) and RPS14 (b)
signatures. (c, d) Heat maps of differentially expressed genes in the
GATA1 (c) and the RPS14 (d) signatures.
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treatment with Rux exerted on the phenotype of Gata1low mice
results very similar to those observed in the patients: it reduced
spleen size and normalized the cellular architecture of this organ
but did not significantly reduced bone marrow fibrosis. Of interest
however, it decreased the megakaryocytes and TGF-β content of
the spleen, suggesting that it mediates its effects indirectly by
normalizing the cellular populations responsible for abnormal
TGF-β production in this organ. These results suggest that
combination therapy with inhibitors of JAK and TGF-β may be
beneficial in the treatment of MF.
In conclusion, these results validate the Gata1low model as a
bona fide model of MF by indicating that these mice express an
activated TPO/MPL axis and an abnormal ribosomal signature,
which may contribute to reduced expression of GATA1 in
megakaryocytes by reducing the efficiency of its mRNA
translation.
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